Friday, 20 Oct 2017

You are here

RheumNow Week in Review - 29 July 2016

Dr Jack Cush reviews this week's highlights from RheumNow.com.

  1. RA: risk of serious infection rises with Interstitial lung dz; 2 fold higher in 1st yr; higher with BOOP & steroids >10mg/day. https://t.co/axzUZhrtHD
  2. FDA warns against using fluoroquinolones (to Rx UTI, bronchitis etc) if other safer Rx options exist. https://t.co/UA0uNmcW3O
  3. Quercetin shown to signif. reduce Uric acid, it inhibits xanthine oxidoreductase in vitro. Not studied in gout. https://t.co/0Fq95UK3PS
  4. CHMP has recommended abatacept for 1st line use (before MTX) in moderate to severe RA. EMA to consider approval https://t.co/kXyD1cXKbO
  5. Anakinra not effective if added to MTX in early RA: CARDERA2 study of 154pts Rx x2yrs. No xray benefit, less DAS/HAQ https://t.co/owvwPhhtss
  6. UK audit of 5000 RA shows only 20% referred from GP to Rheum in 3days (NICE target). Wait time to see Rheum 23-34d https://t.co/5jwIa90EL6
  7. FDA Panel Recommends Brodalumab Approval in Psoriasis
  8. Pravastatin Improves Obstetric Outcomes in Anti-Phospholipid Syndrome Patients. 
  9. Long-Term Safety of Adalimumab Reviewed
  10. MACRA for the Overwhelmed Rheumatologist
  11. The Purse Exam: a Forgotten Part of the Physical. 
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.